LRRC15 and cancer: We employed Syllogist to further assess the proportional distribution of cell types in treated tumors compared to untreated samples.22 In accordance with the expression of LRRC15 in cancer cells originating from mesenchymal stem cells, HuO9 and U118MG tumors displayed a notable overrepresentation of mesenchymal cells across all examined samples, with a significant loss of the mesenchymal cell phenotype in [177Lu]Lu-DUNP19-treated HuO9 cancer cells (Supplementary Fig. 12).